

NOV. 22. 2004 2:56PM

GENAISSANCE PHARM.

RECEIVED
CENTRAL FAX CENTER

NO. 040 P. 1

Application No. 10/019,342
Reply dated November 22, 2004
Office Action mailed November 17, 2004

NOV 22 2004

Application No. : 10/019,342 Confirmation No. 1812
Applicant : Richard S. Judson et al.
Filing Date : December 21, 2001
Title : Methods for Obtaining and Using Haplotype Data
Art Unit : 1631
Examiner : Marianne P. Allen
Attorney Docket No. : 2458-4042US5

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on November 22, 2004.

Melodic W. Henderson
Melodic W. Henderson

REQUEST FOR CORRECTION OF INVENTORSHIP
PURSUANT TO 37 C.F.R. §1.48(a)

This paper is submitted in reply to the Office Action mailed November 17, 2004. The Office Action stated that this application is in condition for allowance, except that an improper Request for Correction of Inventorship had been filed on August 4, 2004.

Applicants hereby request that J. Claiborne Stephens be added as an inventor pursuant to 37 C.F.R. §1.48(a). Enclosed herewith are a statement by the added inventor under §1.48(a)(2) and the assignee's consent under §1.48(a)(5) and §3.73(b). Applicant's note that an oath signed by the newly added and previously named inventors as required under §1.48(a)(3) was included in the previous request submitted August 4, 2004.

Further, Applicants note that the processing fee required under §1.48(a)(5) and §1.17(i) was submitted with the previous request; however, if another processing fee is due, Applicant hereby authorizes the Director to charge a processing fee of \$130.00 to Deposit Account No. 50-1293, which is maintained by Genaissance Pharmaceuticals, Inc., the assignee of this application. A duplicate of this paper is enclosed.

NOV. 22. 2004 3:57PM

GENAISSANCE PHARM.

NO. 040 · P. 2

Application No. 10/019,342
Reply dated November 22, 2004
Office Action mailed November 17, 2004

Upon acceptance of this Request for Correction of Inventorship, Applicants believe that that this application is in condition for allowance and a prompt Notice of Allowance is requested. Should any questions arise, please contact Applicant's undersigned Attorney.

Respectfully submitted,

November 22, 2004
Reg. No. 37,848
Tel. No. 203-786-3421
m.henderson@genaissance.com


Melodie W. Henderson
Melodie W. Henderson
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Application No. 10/019,342
Reply dated November 22, 2004
Office Action mailed November 17, 2004

STATEMENT OF ADDED INVENTOR
PURSUANT TO 37 C.F.R. §1.48(a)

I, J. Claiborne Stephens hereby declare that my name was inadvertently included in the list of inventors to be removed from this application in the Request for Correction of Inventorship submitted November 4, 2003. This error, which arose from a misunderstanding of the claims that were filed with this application, was made without deceptive intent on my part.

I hereby declare that the above statements are made of my own knowledge and are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.


J. Claiborne Stephens

11-22-04
Date

PTO/SB/86 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Genaiissance Pharmaceuticals, IncApplication No./Patent No.: 10/019,342 Filed Issue Date: 12/21/2001

Entitled:

Genaiissance Pharmaceuticals, Inc., a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012458, Frame 0289, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Melodie W. Henderson

Signature

November 22, 2004

Date

Melodie W. Henderson

Printed or Typed Name

203-786-3421

Telephone Number

Vice President, Intellectual Capital + Licensing

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.